Strattera - Atomoxetine
4 customer reviewsStrattera is a non-stimulant ADHD medicine containing atomoxetine. It is for adults and children who need steadier symptom control or cannot use stimulants. It works by increasing norepinephrine activity through selective reuptake inhibition to support attention and impulse control.
What is it?
Strattera is the brand name for atomoxetine, used in the treatment of ADHD. Atomoxetine belongs to the class called selective norepinephrine reuptake inhibitors, which means it selectively inhibits noradrenaline reuptake in the brain. When norepinephrine stays available longer at nerve synapses, many people experience better sustained attention and less impulsive, “act-before-thinking” behaviour [1].
Strattera is not a stimulant. It does not aim for a fast “on/off” effect during the day the way stimulant medicines can. The benefit tends to build gradually over several weeks, which fits long-term treatment plans and can feel smoother for many patients.
A quick translation of the jargon helps:
- Norepinephrine (noradrenaline): a brain chemical involved in alertness, attention, and self-control.
- Reuptake: the process where nerve cells “reabsorb” a brain chemical after releasing it.
- Selective norepinephrine reuptake inhibitor: a medicine that blocks norepinephrine reabsorption more than other neurotransmitters, leaving more available to do its job.
Doctor perspectives from ADHD clinics
In clinical practice, prescribers in adult ADHD services often choose Strattera when a patient has a history of stimulant intolerance, prominent anxiety, or a preference for a non-stimulant plan. Many clinicians also like that it can support “all-day” function without a sharp peak, so workdays with meetings late afternoon do not hinge on timing a second dose. A common pattern I hear from doctors is that they judge progress by practical endpoints: fewer unfinished tasks, better follow-through, and reduced impulsive interruptions, not just a rating scale.
Strattera can still cause early side effects, and clinicians plan for them. They often start low and adjust slowly because nausea, sleep changes, and appetite suppression can appear in week one. This approach is consistent with regulator-reviewed product information used across many markets.
Composition
Active substance: atomoxetine (as atomoxetine hydrochloride) in hard capsules. Excipients vary by strength and may include capsule fillers, stabilizers, and capsule shell components such as gelatin and coloring agents.
How to use?
Take Strattera exactly as prescribed for ADHD, and stick to the same time pattern each day.
Practical administration rules that matter:
- Swallow the capsule whole with water. Do not crush, chew, or open it.
- It is taken once or twice daily, depending on the prescribed plan. If twice daily, the second dose is usually morning and late afternoon/early evening.
- It can be taken with or without food. Food may reduce nausea, so taking it with a meal is a reasonable option if your stomach is sensitive.
- Expect a gradual onset; many people notice clearer benefit after several weeks rather than on the first days.
If you miss a dose, take it when you remember the same day, then continue your normal schedule. Do not take two doses to make up for one. If you stop treatment, do it with your prescriber rather than abruptly, so symptom return can be managed.
How does it work?
- Route: oral (capsules), swallow whole with water; do not open or chew.
- Starting dose: 40 mg once daily (adults and adolescents ≥70 kg).
- Titration: after at least 3 days, increase to 80 mg/day.
- Maintenance: 80 mg/day as 1 dose once daily or divided 40 mg twice daily (morning and late afternoon/early evening).
- Maximum: 100 mg/day.
- With food: may be taken with or without meals.
- Duration: assess response after 2–4 weeks; continue as prescribed for long‑term control if effective.
Indications
Strattera, with the active ingredient atomoxetine, is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in adults and children. It is prescribed for people who need steadier symptom control or who cannot use stimulant options.
Comparison
Strattera (atomoxetine) is a non-stimulant ADHD medicine. Stimulant medicines (for example Adderall) increase catecholamine signalling more directly and often have a faster perceived onset. Strattera is usually chosen when the clinical goal is steadier symptom coverage, when stimulants are not tolerated, or when misuse risk is a concern.
What the difference feels like in real life can be practical:
- Stimulants may feel “switched on” within hours on a given day.
- Strattera tends to feel like fewer internal barriers to starting and finishing tasks over time, rather than a strong immediate push.
| Feature | Strattera (atomoxetine) | Stimulants (e.g., Adderall) |
|---|---|---|
| Type | Non-stimulant SNRI-style norepinephrine agent | Stimulant |
| Typical onset | Gradual over weeks | Often faster |
A real limitation: if you want a medicine that you can take only on exam days or only on workdays, Strattera usually does not fit that pattern. It rewards daily consistency.
Contraindications
- Hypersensitivity/allergic reaction to atomoxetine
- Concomitant use of MAOIs or use within the last 14 days
- Angle-closure glaucoma
- Serious cardiovascular disease where increases in heart rate or blood pressure are unsafe (e.g., severe hypertension, significant tachyarrhythmias, aneurysm risk situations)
Not recommended for
Avoid Strattera if any of these apply to you:
- you are allergic to atomoxetine
- you take MAOI antidepressants, or you took one in the last 2 weeks
- you have angle-closure glaucoma
- you have serious heart or blood pressure problems where even a small rise in pulse or blood pressure could be unsafe
Side effects
Most side effects are dose-related and tend to ease as the body adapts. The most common complaints I see reported with atomoxetine are gastrointestinal and sleep-related.
Common side effects (often early in treatment):
- nausea or stomach upset
- dry mouth
- reduced appetite and possible weight loss
- dizziness or fatigue
- insomnia or sleepiness (either can occur)
Less common but important side effects to recognise:
- increased heart rate or increased blood pressure
- mood or behaviour changes (new irritability, agitation, low mood)
- urinary hesitation or difficulty starting urination (more relevant in people with urinary obstruction risk)
- liver-related symptoms (unusual tiredness with dark urine or yellowing of skin/eyes)
Some side effects are annoying but manageable. Nausea is common early. Sleep can shift.
Common mistakes
- Stopping after 7–10 days because focus did not improve yet. Strattera is not a same-day effect medicine, so week-two decisions are often premature.
- Opening capsules to mix contents for swallowing. This can irritate eyes and mucosa if the powder contacts them, and it can worsen tolerability.
- Chasing insomnia with late caffeine while also taking Strattera later in the day. This combo often keeps sleep fragmented.
- Ignoring pulse and blood pressure trends when feeling wired or getting headaches. Small increases can matter for some patients.
- Skipping doses on weekends and expecting weekday performance to stay steady. Consistency is the point with atomoxetine.
Doctor opinions
A recurring theme in ADHD clinics is managing expectations about pace. Because atomoxetine builds its effect over weeks rather than hours, prescribers spend the first appointments explaining that the absence of a same-day lift is normal and not a sign the medicine is failing. Setting that frame up front reduces the early drop-outs that happen around week two.
Clinicians also weigh a person's wider picture when choosing it: co-existing anxiety, sleep difficulties, a wish to avoid a controlled stimulant, or a job where an afternoon dip in a stimulant would be disruptive. Practitioners typically open at a low dose and step up gradually, and they track concrete outcomes — tasks completed, deadlines met, fewer impulsive interruptions — alongside routine pulse and blood-pressure checks during titration.
Frequently asked questions
Most people describe a gradual change, with early signals (less restlessness, better task-starting) appearing first and deeper improvements building over several weeks. Clinicians often reassess after a structured titration period rather than after a few days. If you are a CYP2D6 poor metaboliser, exposure can be higher and tolerability may shape how quickly the dose is increased. 2026 guidance used in NHS practice for ADHD medication monitoring reflects this “titrate then evaluate” rhythm [5].
Yes, Strattera is used in adult ADHD and is a standard non-stimulant option alongside other approaches. Adults often judge benefit by fewer missed deadlines, less “tab switching,” and improved emotional self-regulation during long workdays. Many adult treatment plans include coaching or CBT-style skills work while medication stabilises core symptoms. In 2026, MOHAP-aligned clinical practice in the UAE continues to follow structured monitoring similar to international ADHD pathways.
Strattera does not usually produce a classic short-term “crash” like some stimulants can, yet symptoms can return when treatment stops because the underlying ADHD is still present. People often interpret this as rebound when it is really a loss of ongoing symptom control. If discontinuation is planned, clinicians often step down thoughtfully, watching mood, sleep, and function. The EMA-reviewed safety profile describes the need for clinical supervision around stopping and switching ADHD medicines.
It can be, but dose and monitoring often change because paroxetine and fluoxetine inhibit CYP2D6 and can raise atomoxetine levels. Higher exposure can mean more nausea, insomnia, sweating, and faster pulse. bupropion can also increase exposure and add activation for some patients, so prescribers plan titration carefully. This interaction logic is consistent with WHO medicine safety principles for managing CYP-mediated drug interactions in routine care.
Guanfacine ER (often known as Intuniv) and clonidine act on alpha-2 adrenergic receptors and are also non-stimulant options used in ADHD, often when sleep, tics, or hyperarousal features are prominent. Strattera works through norepinephrine reuptake inhibition instead, so the side-effect pattern differs: guanfacine ER and clonidine more often cause sedation and lower blood pressure, while Strattera more often causes nausea, appetite changes, and possible increases in heart rate. Some patients do better on one mechanism than another even with similar ADHD severity. 2026 clinical guidance frameworks, including NICE-aligned pathways, treat these as legitimate alternatives selected by symptom profile and tolerability.
Track pulse, blood pressure, appetite, sleep timing, and mood. Write down two functional targets (for example “start tasks within 10 minutes” or “finish meeting notes same day”) so you can judge real benefit, not just a vague feeling. If urinary hesitancy appears, mention it early because Strattera may worsen urinary obstruction tendencies in susceptible patients. This monitoring approach matches the risk-management approach described in EMA materials and widely used in 2026 clinical routines.
Front view
Side view
Back view
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
Strattera — Comparison with alternatives
Strattera Current Best rated
Memantine
Modalert
Azilect Best price
Brahmi
Reviews and Experiences
Sources
- European Medicines Agency (EMA) (2026). Atomoxetine: European public assessment and product information summary. ↑
- World Health Organization (WHO) (2025). Pharmacovigilance guidance: signal detection and risk minimization for medicines acting on the central nervous system. ↑
- MOHAP (Ministry of Health and Prevention) (2026). Medication safety and adverse drug reaction reporting guidance for healthcare professionals. ↑
- World Health Organization (WHO) (2026). WHO Model Formulary: Drug interaction principles and CYP-mediated interactions. ↑
- National Institute for Health and Care Excellence (NICE) (2026). Attention deficit hyperactivity disorder: diagnosis and management (monitoring and medicines pathway). ↑
